EUCTR2020-003874-30-AT进行中（未招募）1 期
A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial - CLARIFY MS Extension
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 380
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participants having participated in the CLARIFY MS trial, who:
- •a. Have at least CLARIFY MS Baseline data on SDMT;
- •b. Received at least a single dose of cladribine tablets in the CLARIFY MS trial; and
- •c. Completed the Final Study Visit (M24) of the CLARIFY MS trial.
- •2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 378
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Participant is considered by the Investigator and Sponsor, for any reason, to be an unsuitable candidate for the study.
- •2. Participation in other studies/trials.
研究者
相似试验
已完成
4 期
A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trialencephalomyelitis disseminataMultiple sclerosis (MS)10007963NL-OMON49089Merck9
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-HUMerck Healthcare KGaA320
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-DKMerck Healthcare KGaA380
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-CZMerck Healthcare KGaA380
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseEUCTR2020-003874-30-ITMERCK KGAA320